Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Salgia

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|July 1, 1997
BCR/ABL induces multiple abnormalities of cytoskeletal functionR Salgia, J L Li, D S Ewaniuk, et al.
The Journal of Biological Chemistry|October 11, 1996
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogeneR Salgia, E Pisick, M Sattler, et al.
The Journal of Biological Chemistry|November 24, 1999
Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteinsY Sun, J Zhang, S K Kraeft, et al.
Scientific Reports|December 5, 2019
Radon exposure is rising steadily within the modern North American residential environment, and is increasingly uniform across seasonsFintan K T Stanley, Jesse L Irvine, Weston R Jacques, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trialR S Herbst, C Lynch, M Vasconcelles, et al.
British Journal of Cancer|February 16, 2012
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerA A Chiappori, M T Schreeder, M M Moezi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2011
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancerD Shumway, K Corbin, R Salgia, et al.
Oncogene|April 4, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Oncogene|August 18, 2015
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, H-T Chen, et al.
Oncogene|June 20, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|July 1, 1997
BCR/ABL induces multiple abnormalities of cytoskeletal functionR Salgia, J L Li, D S Ewaniuk, et al.
The Journal of Biological Chemistry|October 11, 1996
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogeneR Salgia, E Pisick, M Sattler, et al.
The Journal of Biological Chemistry|November 24, 1999
Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteinsY Sun, J Zhang, S K Kraeft, et al.
Scientific Reports|December 5, 2019
Radon exposure is rising steadily within the modern North American residential environment, and is increasingly uniform across seasonsFintan K T Stanley, Jesse L Irvine, Weston R Jacques, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trialR S Herbst, C Lynch, M Vasconcelles, et al.
British Journal of Cancer|February 16, 2012
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerA A Chiappori, M T Schreeder, M M Moezi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2011
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancerD Shumway, K Corbin, R Salgia, et al.
Oncogene|April 4, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Oncogene|August 18, 2015
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, H-T Chen, et al.
Oncogene|June 20, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Pageof 8